Last reviewed 2026-04-23 · How we verify

FMX101

FMX101 is a topical foam formulation of minocycline that reduces bacterial colonization and inflammation in acne-prone skin.

FMX101 is a topical foam formulation of minocycline that reduces bacterial colonization and inflammation in acne-prone skin. Used for Moderate acne vulgaris.

At a glance

Mechanism of action

FMX101 delivers minocycline, a tetracycline antibiotic, in a novel foam vehicle designed for enhanced skin penetration and reduced systemic absorption. The drug works by inhibiting bacterial protein synthesis to reduce Cutibacterium acnes (formerly Propionibacterium acnes) and by suppressing inflammatory pathways involved in acne pathogenesis. The foam formulation improves patient compliance and tolerability compared to traditional oral or topical formulations.

Approved indications

• Moderate acne vulgaris

Common side effects

• Application site irritation
• Erythema
• Dryness
• Photosensitivity

Key clinical trials

• Minocycline as Adjunctive Treatment for Treatment Resistant Depression (PHASE3)
• Optimization of Minocycline for Helicobacter Pylori Rescue Treatment (PHASE4)
• Minocycline in Stroke Study at Maimonides (PHASE2, PHASE3)
• Comparing Two Medicines for Healing Jaw Bone Infections After Root Canal Treatment (NA)
• Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (PHASE2)
• Topical Minocycline for CARP (EARLY_PHASE1)
• Minocycline Efficacy in Improving Neurological Outcome of Patients Who Undergo Endovascular Revascularization for Acute Ischemic Stroke (PHASE2)
• Reconsolidation Blockade of Intrusive Trauma- and Cocaine-related Memories (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.